Vera Therapeutics (VERA) has released an update.
On January 25, 2024, Vera Therapeutics announced promising 72-week results from its Phase 2b ORIGIN trial of atacicept for IgAN, a potential dual inhibitor therapy. The trial showed significant reductions in key indicators of IgAN and stable kidney function among participants. The company is progressing with a Phase 3 trial and anticipates submitting a biologics license application by the second half of 2025, with a potential commercial launch in 2026 if approved. The forward-looking statements highlight the company’s strategic plans and acknowledge the inherent risks and uncertainties in drug development and regulatory approval processes.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.
